Today, with more than 40 cancer immunotherapy indications and over 2,000 clinical trials with cancer immunotherapies, the challenges and issues around patient selection, patient access and side effect management for the community cancer team have grown even more complex. ACCC recognizes and understands these complexities and the rapidly changing IO landscape and strives leading the exchange of solutions to proactively address the operational, optimization, research and educational challenges associated with cancer immunotherapies for the community cancer care team.
The Association of Community Cancer Centers Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for cancer care teams across all healthcare settings.
Since 2015, ACCC has led the only initiative to prepare all members of the multidisciplinary cancer care for the complex implementation of immuno-oncology in the community setting.
Care Coordination & Immune-Related Adverse Events: Building a Multispecialty Immuno-Oncology Checkpoint Inhibitors Toxicity TeamDownload Article & Companion Guide
Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community
Two ACCC member programs are participating in "Overcoming Obstacles in Integrating Immunotherapies for Cancer in the Community Setting," a quality improvement research study. Learn more and view the study design.
Peer-to-peer learning focused on practical “how to’s” for integrating immunotherapy into practice in the community setting with a focus on physical space considerations, workflow, staffing, patient education, and lessons learned.
The rapid pace of new approvals and indications in immunotherapy for cancer requires ongoing education to understand the spectrum of immune-related adverse events (irAEs) and how to effectively manage your patients’ irAEs using a multidisciplinary approach.
ACCC Immuno-Oncology Institute Executive Committee member Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments.